Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | TLN-372 |
| Synonyms | |
| Therapy Description |
Limited information is currently available on TLN-372, a putative pan-KRAS inhibitor (Oct 2025). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| TLN-372 | TLN372|TLN 372 | KRAS Inhibitor 30 | Limited information is currently available on TLN-372, a putative pan-KRAS inhibitor (Oct 2025). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07204340 | Phase I | Pembrolizumab + TLN-372 Cetuximab + TLN-372 TLN-372 | TLN-372 in Advanced KRAS Mutant Solid Tumors | Recruiting | USA | AUS | 0 |